Skip to content

Evaluation of a New Regional Organization to Promote Access to Renal Transplantation

Promoting Access to Renal Transplantation: Impact of a Patient-centered Regional Organization

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03234075
Acronym
TRACE
Enrollment
4000
Registered
2017-07-31
Start date
2018-01-01
Completion date
2023-01-01
Last updated
2020-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal Failure

Brief summary

Patients with terminal chronic kidney disease (CRD) need renal function supplementation, namely dialysis or renal transplantation. Transplantation is the most efficient and cost-effective treatment. Early and equitable access to transplantation is a public health issue. Access to transplantation is facilitated by early and systematic information and assessment of patients for inclusion in the national waiting list for transplantation prior to the onset of dialysis, and by the development of transplantation from living donors. In France, there are wide disparities in access to national waiting list registration and transplantation. One of the causes of these inequalities in access would be the disparity in referral practices to a transplant medical and surgical team authorized to register the individual on the national waiting list. The aim of the TRACE study is to evaluate the impact of a new regional organization promoting renal transplantation on access to renal transplantation.

Interventions

OTHERRegional organization for promotion of renal transplantation

Early identification of candidates for renal transplantation * with the help of a care coordinator Inform all patients appropriately about the techniques of renal function supplementation * delivered by expert patients and a care coordinator Assist the nephrologists in patient graft pathway * Multidisciplinary assessment of patients in dedicated web-conferencing meetings bringing together nephrologists and transplant team ( WebRCP of kidney transplant orientation) * Helping to carry out the pre-graft assessments of patients by a care coordinator

Sponsors

Hospices Civils de Lyon
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to 84 Years
Healthy volunteers
No

Inclusion criteria

* Patient older than 18 years and younger than 85 years. * Entered in the French Network Epidemiology and Information in Nephrology register * Renal function supplementation begun in 2013 -- 2014 (period before regional organization implementation) or in 2018 -- 2019 (period after regional organization implementation).

Exclusion criteria

\- Patient followed in a Center of nephrology-dialysis or of Renal transplantation located outside French Auvergne Rhône Alpes or Center Regions.

Design outcomes

Primary

MeasureTime frameDescription
Cumulative incidence rate of access to renal transplantation for patients with end-stage renal failureAt 24 months after initiation of renal function supplementationAccess to renal transplantation is defined by: * Pre-emptive renal transplantation with living donor or deceased donor * Registration on the national waiting list for renal transplantation

Countries

France

Contacts

Primary ContactMyriam PASTURAL-THAUNAT, Dr
myriam.pastural-thaunat@chu-lyon.fr04 72 11 01 50
Backup ContactKarine POYAU
karine.poyau@chu-lyon.fr04 72 11 53 81

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026